Nuveen Asset Management LLC Buys New Stake in Natus Medical Incorporated (BABY)

Nuveen Asset Management LLC acquired a new position in Natus Medical Incorporated (NASDAQ:BABY) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 10,081 shares of the medical equipment provider’s stock, valued at approximately $396,000.

Several other large investors have also made changes to their positions in BABY. BlackRock Inc. raised its stake in shares of Natus Medical by 137,510.8% in the first quarter. BlackRock Inc. now owns 4,124,195 shares of the medical equipment provider’s stock worth $161,874,000 after buying an additional 4,121,198 shares during the last quarter. Columbia Wanger Asset Management LLC raised its stake in shares of Natus Medical by 243.6% in the first quarter. Columbia Wanger Asset Management LLC now owns 2,030,207 shares of the medical equipment provider’s stock worth $79,686,000 after buying an additional 1,439,382 shares during the last quarter. Wellington Management Group LLP raised its stake in shares of Natus Medical by 105.7% in the first quarter. Wellington Management Group LLP now owns 1,795,094 shares of the medical equipment provider’s stock worth $70,457,000 after buying an additional 922,268 shares during the last quarter. Epoch Investment Partners Inc. raised its stake in shares of Natus Medical by 68.3% in the first quarter. Epoch Investment Partners Inc. now owns 1,110,932 shares of the medical equipment provider’s stock worth $43,604,000 after buying an additional 450,698 shares during the last quarter. Finally, Norges Bank acquired a new stake in shares of Natus Medical during the fourth quarter worth $11,560,000. Hedge funds and other institutional investors own 95.66% of the company’s stock.

Natus Medical Incorporated (BABY) opened at 32.50 on Friday. The stock has a market capitalization of $1.06 billion, a P/E ratio of 56.33 and a beta of 0.93. Natus Medical Incorporated has a 52 week low of $32.45 and a 52 week high of $44.39. The company has a 50 day moving average of $36.08 and a 200 day moving average of $36.52.

Natus Medical (NASDAQ:BABY) last issued its quarterly earnings results on Wednesday, July 26th. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.01. The company had revenue of $122.20 million during the quarter, compared to the consensus estimate of $121.99 million. Natus Medical had a return on equity of 12.09% and a net margin of 4.20%. Natus Medical’s revenue was up 27.3% on a year-over-year basis. During the same period last year, the company earned $0.39 earnings per share. Equities analysts expect that Natus Medical Incorporated will post $1.70 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was reported by BNB Daily and is owned by of BNB Daily. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.baseball-news-blog.com/2017/08/19/nuveen-asset-management-llc-buys-new-position-in-natus-medical-incorporated-baby-updated-updated.html.

A number of equities research analysts have recently weighed in on BABY shares. TheStreet lowered shares of Natus Medical from a “b” rating to a “c+” rating in a report on Thursday, April 27th. Zacks Investment Research lowered shares of Natus Medical from a “hold” rating to a “sell” rating in a report on Friday, July 28th. BidaskClub raised shares of Natus Medical from a “sell” rating to a “hold” rating in a research note on Saturday, July 1st. Finally, Benchmark Co. reaffirmed a “buy” rating and issued a $48.00 target price (down from $55.00) on shares of Natus Medical in a research note on Monday, May 1st. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company’s stock. Natus Medical presently has a consensus rating of “Hold” and a consensus price target of $45.00.

In other Natus Medical news, Director Doris Engibous sold 5,000 shares of the stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $32.68, for a total value of $163,400.00. Following the sale, the director now owns 22,650 shares in the company, valued at $740,202. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director William M. Moore sold 3,000 shares of the stock in a transaction on Monday, August 14th. The stock was sold at an average price of $34.10, for a total value of $102,300.00. Following the completion of the sale, the director now owns 30,410 shares in the company, valued at approximately $1,036,981. The disclosure for this sale can be found here. 5.50% of the stock is owned by company insiders.

About Natus Medical

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.

Institutional Ownership by Quarter for Natus Medical (NASDAQ:BABY)

Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply